These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 24065375)

  • 1. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
    Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ
    Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study.
    Rosiak M; Postuła M; Kapłon-Cieślicka A; Trzepla E; Filipiak KJ; Członkowski A; Opolski G
    Kardiol Pol; 2013; 71(6):552-7. PubMed ID: 23797426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients.
    Postula M; Janicki PK; Rosiak M; Przybylkowski A; Kaplon-Cieslicka A; Grygorowicz T; Trzepla E; Filipiak KJ; Czlonkowski A; Opolski G
    Cardiol J; 2013; 20(2):170-7. PubMed ID: 23558875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: the AVOCADO study.
    Rosiak M; Postula M; Kaplon-Cieslicka A; Kondracka A; Trzepla E; Czlonkowski A; Janicki PK; Filipiak KJ; Opolski G
    Cardiol J; 2013; 20(5):545-51. PubMed ID: 24469880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus.
    Lemkes BA; Bähler L; Kamphuisen PW; Stroobants AK; Van Den Dool EJ; Hoekstra JB; Nieuwland R; Gerdes VE; Holleman F
    J Thromb Haemost; 2012 Apr; 10(4):639-46. PubMed ID: 22252020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Platelets; 2011; 22(3):188-95. PubMed ID: 21231857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study.
    Kaplon-Cieslicka A; Postula M; Rosiak M; Peller M; Kondracka A; Serafin A; Trzepla E; Opolski G; Filipiak KJ
    Cardiovasc Diabetol; 2014 Aug; 13():112. PubMed ID: 25123549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
    Larsen SB; Grove EL; Kristensen SD; Hvas AM
    Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays.
    Can MM; Tanboğa IH; Türkyilmaz E; Karabay CY; Akgun T; Koca F; Tokgoz HC; Keles N; Ozkan A; Bezgin T; Ozveren O; Sonmez K; Sağlam M; Ozdemir N; Kaymaz C
    Thromb Res; 2010 Apr; 125(4):e132-7. PubMed ID: 19954823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for aspirin resistance in stable coronary artery patients by three different tests.
    Chakroun T; Addad F; Abderazek F; Ben-Farhat M; Hamdi S; Gamra H; Hassine M; Ben-Hamda K; Samama MM; Elalamy I
    Thromb Res; 2007; 121(3):413-8. PubMed ID: 17553552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.
    Homoncik M; Jilma B; Hergovich N; Stohlawetz P; Panzer S; Speiser W
    Thromb Haemost; 2000 Feb; 83(2):316-21. PubMed ID: 10739392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels.
    Gonçalves LH; Silva MV; Duarte RC; Dusse LM; Fernandes AP; Bosco AA; Gomes KB; Carvalho Md
    Clin Chim Acta; 2014 Feb; 429():76-8. PubMed ID: 24316050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors responsible for "aspirin resistance" - can we identify them?
    Postuła M; Tarchalska-Kryńska B; Filipiak KJ; Kosior D; Serafin A; Huczek Z; Opolski G
    Kardiol Pol; 2010 Apr; 68(4):403-11; discussion 412-3. PubMed ID: 20425699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional evaluation of platelet aspirin resistance after on-pump coronary bypass grafting using multiple aggregation tests.
    Kammerer I; Bach J; Saggau W; Isgro F
    Thorac Cardiovasc Surg; 2011 Oct; 59(7):425-9. PubMed ID: 21437867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?
    Postula M; Rosiak M; Kaplon-Cieslicka A; Kondracka A; Trzepla E; Filipiak KJ; Czlonkowski A; Opolski G
    Cardiol J; 2012; 19(5):494-500. PubMed ID: 23042313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus.
    Gurbel PA; Bliden KP; Chaudhary R; Patrick J; Liu F; Chen G; McLeod C; Tantry US
    Am J Cardiol; 2016 Dec; 118(12):1941-1947. PubMed ID: 27769511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity.
    Lee S; Eichelberger B; Kopp CW; Panzer S; Gremmel T
    Vascul Pharmacol; 2021 Feb; 136():106819. PubMed ID: 33207279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
    Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
    Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
    Serebruany VL; Malinin AI; Pokov A; Barsness G; Hanley DF
    Am Heart J; 2008 Jan; 155(1):93.e1-7. PubMed ID: 18082496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.